Global Healthcare Mobility Solutions Market Driven by Rising Number of Mobile Devices and Presence of High-speed Internet Connectivity

In recent years, mobility has emerged as a crucial technology for the healthcare industry, as it enables the medical community to adopt a patient-centric approach, minimizing healthcare costs and the implications of the shortage of nursing and healthcare professionals. Increasing penetration of smartphones, tablets, and PDAs coupled with the growing focus on patient-centric applications is driving the healthcare mobility solutions market. Furthermore, advancements in network technologies (3G and 4G) and a shortage of nursing staff and healthcare professionals is expected to have a positive impact on the growth of the healthcare mobility solutions market. The security and privacy issues and interoperability challenges associated with the mobility solution have somewhat limited the widespread adoption of healthcare mobility solutions.

In terms of product and services, the mobile devices segment was the largest contributor to the global healthcare mobility solutions market in 2014 and is expected to remain the dominant product segment over the forecast period. The dominance can be attributed to increased penetration of mobile computers, smartphones, RFID scanners, tablets, and PDAs, which help healthcare service providers adopt a patient-centric approach and streamline their workflow. However, mobile applications are expected to witness the maximum adoption over the forecast period, expanding at a CAGR of 25.8%. In 2014, the enterprise solutions segment was the largest application segment, accounting for 53.1% of the market revenue. Factors such as increasing focus on healthcare cost savings and a rising demand for home healthcare services are collectively expected drive the growth of mHealth applications over the forecast period.

The healthcare service providers segment, covering hospitals, laboratories, and other healthcare facilities, was the largest end-use segment, accounting for 45.4% of the global market revenue in 2014. It is expected to remain the largest end-use segment throughout the forecasted period. However, the patients (individuals) segment is expected to exhibit the maximum growth, expanding at a CAGR of 25.8% over the forecast period. The expected growth can be attributed to increasing health awareness among consumers, availability of smart healthcare devices, and the rise in healthcare spending by consumers.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4773

Increased Accessibility to Mobile Devices and the Internet Propels Market

A research undertaken by Alego Health, a U.S.-based healthcare IT services and solutions provider, over 72% nurses and 62% doctors in the U.S. were using smartphones and tablet computers in healthcare settings in 2012. The study also states that nearly 247 mn people in the U.S. in the same year downloaded mobile healthcare apps for personal use. By that year, over 40,000 healthcare mobile apps were available in the market, the number of which has consistently increased ever since.

The high rate of adoption of mobile devices in healthcare facilities, the unprecedented pace at which technological advancements are taking place in the field of mobile connectivity, and the improved network of high-speed Internet across the globe are the key factors propelling the healthcare mobility solutions market.

North America was the largest healthcare mobility solutions market, accounting for 44.6% of the global revenue in 2014. Over the forecast period from 2015 to 2023, it is expected to retain this position owing to the established healthcare and communications infrastructure in the region. Asia Pacific is expected to witness maximum growth over the forecast period from 2015 to 2023, expanding at a CAGR of 28.3%. Some of the leading players in the market are McKesson Corporation (the U.S.), Cerner Corporation (the U.S.), Koninklijke Philips N.V. (The Netherlands), SAP SE (Germany), Oracle Corporation (the U.S.), AT&T, Inc. (the U.S.), and Cisco Systems, Inc. (the U.S.).

Cancer stem cells (CSCs) refer to the cells obtained from tumor that posses potential to reproduce all types of cancer cells found in a cancer sample. Cancer stem cells are planned to grow in tumors as a separate population and thereby cause deterioration and metastasis of existing tumor through generation of new tumor. Thus, with advancement in technology especially in cancer stem cells research area, therapies specific to targeting cancer stem cells are expected to improve quality of life and survival cases of cancer patients with metastatic diseases.

Morbidity and mortality rate of cancer is rising at a faster speed worldwide and thus prevention of cancer and cancer treatment is grabbing attention of cancer researchers globally. Stem cells and cell therapy have shown significant potential to treat cancer effectively. Cancer stem cells (CSCs) have been tested on animal models and have also shown satisfactory results. However, human testing of cancer stem cells is still in its developing stage owing to stringent regulations and ethical issues associated with the same.

Worldwide cancer research activities are increasing rapidly owing to rising burden of mortality rate of cancer. Cancer stem cells are under research for various types of cancers such as lung cancer, breast cancer, colorectal cancer, skin cancer, brain cancer and bone cancer. Government initiative to boost the cancer research activities and availability of funds are some of the factors that are driving the global cancer stem cells (CSCs) market towards growth. While on the other hand, ethical issues involved in the stem cells research and stringent regulations to perform human trials are some of the factors that are restraining the growth of the global cancer stem cells (CSCs) market.

Geographically, global cancer stem cells market is segmented into North America, Europe, Asia Pacific and Rest of the world (RoW) regions. Currently, North America is leading the global cancer stem cells (CSCs) market and is followed by Europe. Factors such as highly developed research infrastructure, well defined regulatory norms, availability of research funds, availability of skilled research and healthcare professionals and supportive economy are driving the North American cancer stem cells market towards growth. Asia Pacific is lucrative market for cancer stem cells. Governments in the Asia Pacific countries mainly, India and China are taking initiative to boost the healthcare and biotechnology industry in the respective countries and thus, research and development activities in these countries are swiftly increasing.

Request Sample for this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2733

Apart from India and China, Japan will play a significant role in the cancer stem cells market. Japanese government is heavily investing in healthcare industry in order to improve the healthcare facilities in the country and thus rising cancer treatment are expected to escalate the cancer stem cells treatment market in Japan. Latin American countries namely, Brazil, Mexico and Argentina are expected to contribute more to cancer stem cells market than other countries in the rest of the world region. While on the other hand, African countries and Middle Eastern countries are expected to show slow or no growth rate in the global cancer stem cells (CSCs) market.

Some of the major players in the global cancer stem cells market are AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.

Detection is Better than Cure: Understanding the Various Factors Causing Anxiety Disorders and Depression

According to the World Health Organization (WHO), depression and anxiety disorders, including stress-related psychiatric conditions, would rival cardiovascular diseases by 2020 as the major health disorder with the highest disease burden globally. Antidepressants and anxiolytics are the medications used to treat various types of depression and anxiety disorders and prevent them from recurring. Anxiety is a natural reaction to stress, trauma and fear, which can be experienced by everyone at times. However, when this condition becomes severe, it might challenge an individual’s capability to lead a normal life. Similarly, depression is a state of low mood and aversion to daily activities that can affect an individual’s feelings, thoughts, sense of well-being and behavior. Various researches reveal that anxiety disorders and depression are the major risk factors for suicide among humans. Over 90% of individuals who commit suicide have some sort of diagnosable mental illness. It has also been reported that depression and anxiety disorders are more prevalent in developed economies such as the U.S., Canada, France, Germany, the U.K., and Italy due to the high levels of work-associated stress, personal relationships, societal factors, environmental factors as well as genetic aspects prevalent in these geographies.

Presently, the global anxiety disorders and depression treatment market is on a decline due to patent expiry of major antidepressants, weak pipeline of novel drugs and increasing number of generic drug variants. However, driving factors such as increasing prevalence of anxiety disorders and depression and rising geriatric population prone to psychiatric disorders are expected to offset the declining growth of the market in the near future.

The anxiety disorders and depression treatment market has been segmented based on drug classes most commonly used for the treatment and prevention of psychiatric disorders. Based on drug classes, the market has been segmented into selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCA), monoamine oxidase inhibitors (MAOIs), benzodiazepines, atypical antipsychotics, anticonvulsants and beta blockers. SNRIs accounted for the largest share of the depression treatment market in 2013. However, the segment is expected to witness a decline in revenue during the forecast period. Patent expirations of leading branded formulations such as Cymbalta and Effexor XR coupled with growing influx of generic formulations are some of the major factors expected to affect the growth of the segment. Similarly, SSRIs accounted for the largest share of the anxiety disorders treatment market in 2013. However, the market for SSRIs is expected to decline due to patent expirations, growing prevalence of treatment-resistant psychiatric disorders and high adoption rate of generic drugs.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1199

North America is the largest market for anxiety disorders and depression treatment drugs due the presence of large patient population suffering from various types of anxiety disorders and depression. However, the anxiety disorders and depression treatment market in the U.S. is currently saturated, as several antidepressant drugs are available on prescription for the same indication. Hence, the future growth of the market would depend on introduction of efficacious drugs for new indications. Moreover, loss of patent exclusivity, market maturity, generic infiltration and shortened drug lifecycles are the additional factors that contribute to the decline in market growth in the region. Asia Pacific is expected to witness an appreciable growth due to multiple factors such as high prevalence of psychiatric disorders and rapid economic growth in countries such as China, Japan and Australia. Additionally, positive marketing approval for innovative medicines is likely to drive the market in the near future.

Currently, the market is highly fragmented and competitive in nature due to the involvement of both large and small pharmaceutical companies. AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Sanofi S.A. are major companies operating in the anxiety disorders and depression treatment market. Majority of the market players are focusing on expanding distribution network as well as expanding geographical presence, as Asia Pacific, the Middle East, and Latin America are developing regions with an increasing prevalence of various types of anxiety disorders and depression and improving economic conditions.

Adoption of Tele-health Services to Fuel the Growth of Global Endocrine Testing Market

A new Transparency Market Research report states that the global endocrine testing market, pegged at US$6.1 bn in 2014, is predicted to reach US$12.8 bn by 2023, by rising at a CAGR of 8.50% from 2015 to 2023. The title of the report is “Endocrine Testing Market - Global Industry Analysis, Size, Share, Growth Trends and Forecast, 2015 - 2023.”

Endocrine hormones and glands constitute the endocrine system and secrete hormones that are significant for the regulation of numerous body mechanisms such as development, growth, and homeostasis. The endocrine system also helps in the management of responses to injuries and stress, maintenance of water, balance of electrolytes, and nutrient absorption, among others. A number of tests are performed for monitoring endocrine hormone levels. These tests help in detecting deviations in the hormone production process that may result in certain kinds of endocrine disorders including menopause, thyroid dysfunction, infertility, and others.

According to the report, the rising aging population and increasing obese and diabetic population globally are amongst the chief factors stimulating the growth of the endocrine testing market. In addition, a number of technological advancements have also created new growth opportunities in the market. On the other hand, factors such as the absence of healthcare awareness in developing nations and the soaring cost of technology may inhibit the growth of the market in the coming years.

On the basis of test, the report segments the market into estradiol (E2) test, follicle stimulating hormone (FSH) test, human chorionic gonadotropin (hCG) test, luteinizing hormone (LH) test, dehydroepiandrosterone sulfate (DHEAS) test, progesterone test, testosterone test, thyroid stimulating hormone (TSH) test, prolactin test, cortisol test, insulin test, and others (gastrin, thymosin, secretin, etc). Amongst these, the segment of TSH led the market in 2014 and is predicted to maintain its dominance throughout the forecast horizon. This is owing to the increasing occurrence of thyroid disorders amongst the aging population in this region. On the other hand, the segment of insulin testing is predicted to be the most swiftly developing segment in the forecast horizon.

By technology, the market is segmented into tandem mass spectrometry, immunoassay (enzyme immunoassays, radioimmunoassays (RIA)) technologies, monoclonal and polyclonal antibody technologies, sensor (electrochemical, biosensors, etc.) technologies, clinical chemistry technologies, and others (liquid chromatography + mass spectrometry (LC-MS)). Amongst these, the segment of immunoassay led the market in 2014 and is predicted to expand at a 9.10% CAGR from 2015 to 2023.

Get a Sample for this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1645

By end use, the report segments the market into commercial laboratories, hospitals, ambulatory care centers, physician offices, and home-based tests. Commercial laboratories led the market in 2014 and are poised to rise at a 9.30% CAGR between 2015 and 2023. On the other hand, home-based tests are predicted to experience the highest growth rate in the forecast horizon owing to the rising preference of customers for instant test results globally.

Geographically, the report segments the market for endocrine testing into Asia Pacific, North America, Europe, and Rest of the World (RoW). In 2014, North America constituted the largest share in the market for endocrine testing owing to the rising healthcare awareness amongst patients and the increasing occurrence of obesity and diabetes here. However, Asia Pacific is the most promising market for endocrine testing and is predicted to rise at the highest CAGR of 10.30% between 2015 and 2023.

F-Hoffman La Roche Ltd., Abbott Laboratories, DiaSorin, Agilent Technologies, and Siemens Healthcare, among others, are the major players operating in the market, as per this study.

Life Science Reagents Market to Reach US$25.7 bn by 2020 owing to Rising Activities of R&D within the Field of Pharmaceuticals

Life science reagents include reagents that are used in biotechnology, bioscience and pharmaceutical industries. Since the last decade, the global life science reagents market has experienced impressive growth due to factors such as technology advancement and expansion in applications of biotechnology and biosciences in the field of healthcare and pharmaceuticals. Some other factors contributing to the growth of the life science reagents market include increasing disease prevalence and rise in their mortality rates, aging of population and increased research and development activities in the field of biosciences, biotechnology and pharmaceuticals. Based on the commercially available life science reagent products, the global life science reagents market is categorized as PCR reagent kits, cell and tissue culture reagents, flow cytometry reagents, electrophoresis reagents, chromatography reagents, in-vitro diagnostic reagents and others. In addition, the global life science reagents market is segmented on the basis of end users, namely, commercial and contract manufacturers, research and academics, clinical laboratories, and forensic laboratories.

Chromatography reagents are the most widely used reagent products thus, capturing the highest market share in the overall life science reagents market. Wide use of chromatography in almost every aspect of biotechnology-related research and product development is the prime contributing factor for the dominance of this segment. On the other hand, the market share of electrophoresis reagents is the lowest as compared to other products available in the overall life science reagents market. Technological advancement and increasing initiatives towards the expansion of scope of biotechnology and life science has led to perpetual rise in demand for life science reagents worldwide.

In terms of end users, research and academic institutions are the largest consumers of life science reagents. Technological development and corresponding rise in the number of available skilled labor in emerging economies have widened the scope for research outsourcing in the developing markets of India and Brazil. Processes such as pharmaceutical contract manufacturing and cosmetic product manufacturing constitute the largest commercial consumers of life science reagents. Due to the requirement of high capital investment to perform stability studies, formulation development and phase-I trials, several pharmaceutical companies outsource drug development operations to contract manufacturing companies to focus on their core activities of manufacturing drugs and marketing, thereby controlling the in-house budget.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1162

The global life science reagents market is fragmented in terms of presence of a large number of multinational and local players. The mature market players such as Sigma Aldrich, Abbott Laboratories, Life Technologies, Bio-Rad and others currently dominate this market with their patent protected products and intensive growth strategies of acquiring new market entrants providing breakthrough technologies. In addition, large patent repositories of the established market players restrains the entry and growth of new players in the life science reagents market.

Geographically, North America dominates the global life science reagents market and is followed by Europe. Asia-Pacific is expected to show the highest growth rate owing to factors such as increasing research and development activities, rise in the number of government aids, business clusters and trade conglomerates to strengthen biotechnology industry in the respective national markets and rise in the availability of skilled manpower at cheaper cost, thereby increasing the scope for outsourcing of biotech projects. New trend of outsourcing research activities in Asia-Pacific is one of the major driving forces for the growth of the life science reagents market in this region. Countries such as Brazil, Mexico and Argentina in the Rest of the World (RoW) region are adopting strategies such as formation of biotechnology clusters and attracting foreign investments to boost the domestic biotechnology industry. However, stringent regulatory rules restrain the entry of new products in the market and thus, restrict the growth of life science reagents market in these countries.

Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 owing to Global Rise in Diabetes and Obesity

Increasing adherence to a deceptive destructive modern lifestyle, intensifying schedules, and unhealthy dietary and other lifestyle choices are the most widespread consequences of urbanization. The situation has inevitably led to a growing incidence of chronic lifestyle diseases all over the world. Cardiovascular diseases, for instance, are now looked upon as one of the leading causes of death around the world. According to the WHO (World Health Organization), cardiovascular diseases will remain the leading cause of death worldwide until 2030.Physical inactivity, unhealthy diet, and growing prevalence of addictions such as smoking have been cited as the most common underlying causes of cardiovascular diseases. These also are the most effective causative agents leading to hypertension and obesity, which again are two of the most common conditions associated with cardiovascular diseases. The rapidly increasing number of patients diagnosed with peripheral artery diseases, congenital heart diseases, pulmonary embolisms, and coronary artery diseases has spurred the demand for precautionary healthcare. Hence, demand for cardiovascular monitoring devices has risen in recent years.

According to a recent report published by Transparency Market Research, the global cardiovascular monitoring devices market, which stood at US$3.7 billion in 2012, will expand at a healthy 9.7% CAGR to reach a valuation of US$7.0 billion by 2019.

Aging Population and Technology Advances to Boost Global Market

The globally increasing incidence of cardiovascular diseases can be largely attributed to the growing geriatric population. The risk of diabetes and hypertension enhances with age, which in turn boosts the demand for cardiovascular diagnostic devices. Moreover, the advent of compact and precise therapeutic and diagnostic devices have made it possible to conduct tests through portable devices, which, according to experts, will significantly bolster the global cardiovascular monitoring devices market. The medical world today has been introduced to wearable medical devices such as heart rate monitors and technologies like implantable loop recorders. This has compelled leading players to pace up innovation, which in turn will propel the market.

Demand for ECG Systems to Remain High

The popular product types encompassed within the ambit of the cardiovascular monitoring devices market are ECG systems, holster monitors, cardiovascular diagnostic catheters, event monitors, ECG management systems, and implantable loop monitors. The demand for ECG systems has surged ahead of its contemporaries owing to the convenience and low cost of the procedure. However, while ECG systems dominated the market for cardiovascular monitoring devices in 2012, recent trends indicate encouraging prospects for the implantable loop monitors segment in the foreseeable future.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2385

Asia Pacific to Emerge as Fastest Growing Cardiovascular Monitoring Devices Market

The key geographical segments of the cardiovascular monitoring devices market are North America, Asia Pacific, Europe, and Rest of the World. North America has always remained in the vanguard of technological innovations, which is one of the key reasons why the demand for cardiovascular diagnostic devices is the highest from this region.Widespread awareness among patients is likely to keep the demand for cardiovascular diagnostic devices high in North America in the near future as well. However, the growing prevalence of cardiovascular ailments in Asia Pacific, together with increasing patient population and healthcare expenditure, will help the region emerge as the fastest growing cardiovascular monitoring and diagnostic devices market in the forecast period.

Leading Players in Skin Replacement Market

Global Skin Replacement Market: Overview

The skin, which is the largest external organ in the human body, is also easily prone to injuries and damage. It is formed of two protective layers – while the epidermis is the outer layer of the skin, the dermis in the layer that lies just beneath the epidermis. It is imperative that the skin functions properly because it protects the musculoskeletal system, important organs, and regulates the fluid levels in and temperature of our body.

Skin diseases such as eczema, psoriasis, and skin cancer can be a painful experience and one that can also compromise a person’s quality of life. Likewise, injuries and trauma to the skin can affect a person’s ability to lead a normal life. Moreover, the impact of various diseases and injuries can prevent the skin from performing its normal functions even after it has healed. However, these issues can be addressed to a large extent by using artificial skin. The availability of artificial skin has today led the emergence of a worldwide market for skin replacement techniques and technologies.

The roots of this market can be traced back to the early 1980s when John F. Burke of the Massachusetts Institute of technology co-invented synthetic skin. Since then, several advances have been made to the way artificial skin is produced. It has been a boon to people who have suffered from severe burns and patients of skin diseases. It has now become easier for medical experts to rapidly graft artificial skin or produce it in large quantities. Newer varieties of artificial skin can be stored at room temperature and can also be sterilized easily.

The skin replacement market is thus being shaped by numerous trends that will contribute to its healthy growth. The market is especially being driven by the use of advanced skin replacement therapies in treating chronic skin wounds and severe skin burns.

Global Skin Replacement Market: Important Drivers and Restraints

The continued efforts being directed at improving the efficacy of artificial skin have helped the global skin replacement market grow steadily over the years. This has also helped in the expansion of the current base of products available on the market, giving consumers access to specific skin replacement therapies in line with their existing condition. It is interesting to note that every time a new artificial skin product is launched on the market, more niches are being created in this space.

The ability of consumers to spend on these products has further encouraged companies to bring newer products to the market. A rise in the number of skin diseases and injuries and the consciousness among consumers to have healthy-looking skin are all helping the skin replacement market grow in size.

The future of the global skin replacement market lies in bioengineered skin replacements. These are a relatively newer class of products but are capable of being developed to closely mimic virtually every function of natural skin. However, the market does continue to face competition from lower-priced substitutes.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11672

Global Skin Replacement Market: Segmentation and Region-wise Outlook

The market for skin replacement can be broadly segmented basis material used and end user. The two most common materials used for producing artificial skin are collagen and spider silk. The uses of artificial skin are widely seen in cosmetic, pharmaceutical, and chemicals sectors.

From the geographical standpoint, the global market for skin replacement can be segmented into Asia Pacific, North America, Europe, and Rest of the World. The market for skin replacement in North America contributes a sizeable portion to the global market revenues. With countries in Asia Pacific offering attractive medical tourism packages to patients worldwide, the demand for skin replacement is expected to rise in these regions.

Companies at the forefront of the global skin replacement market are: Cynata Therapeutics Limited, Cellular Dynamics International, Platelet BioGenesis, TissueGene, Inc., and Tengion.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

CA Tumor Markers Testing Market Trends and Forecast 2016 – 2023

CA Tumor Markers Testing Market: Overview

Tumor markers are biological substances found in the body tissues, blood and urine; that can be elevated when a person is suffering from cancer. Tumor markers are normally made of cancerous cells or by the body in response to cancer. Traditional tumor markers are proteins; however newer tumor markers are genetic substances. There are various types of cancer antigen (CA) tumor markers each indicative of a specific disease mechanism; and these tumors are used in oncology to help in the detection of cancer of a particular organ or site. An elevated level of a CA tumor marker can signify various forms of cancer such as breast cancer, colorectal cancer and ovarian cancer. Currently, the CA tumor marker testing market is a lucrative thanks to the high numbers of patients opting for such testing and the increasing base of cancer patients, which makes this industry not only highly profitable but also attractive to investors.

Some of the technologies used for the detection of CA tumor markers are as follows:

• Radioimmunoassay (RIA)
• Enzyme Immunoassays (EIA)
• PCR
• Latex Agglutination
• Immuno-PCR
• Nucleic acid sequence based amplification (NASBA)

Some of the types of cancer antigen marker usually used for cancer tumor testing are as follows:

• Cancer Antigen 125 (CA 125), used for detecting epithelial ovarian cancer
• Cancer Antigen 27-29 (CA 27-29), used for detecting breast cancer
• Cancer Antigen 19-9 (CA 19-9), used for detecting colorectal cancer
• Cancer Antigen 15-3 (CA 15-3), used for detecting breast cancer
• CA Tumor Markers Testing Market: Regional Overview

From the geographical perspective, North America stands as the largest market for CA tumor markers testing owing to the large base of cancer patients. According to the American Cancer Society, approximately 1,660, 290 new cases of cancer were diagnosed in 2013. Another report published by the WHO, it was estimated that globally 14.1 million new cases of cancer were diagnosed and almost 8.2 million deaths related to cancer occurred in 2012.

However, other regional markets such as Southeast Asia, the Middle East, and Latin America are projected to be the potential markets in the near future. This can be ascribed to the increasing levels of disposable income among the population and the high rate of adoption of advanced cancer screening tools. It is expected that these emerging regions will be high-potential markets in the near future.

CA Tumor Markers Testing Market: Drivers

The overall CA tumor marker testing market is witnessing a remarkable growth owing to the increasing rate of incidence of cancer and other non-communicable disorders. Moreover, increasing geriatric population will further fuel the growing demand for tumor assays and novel cancer therapeutics globally. Moreover, trends show that the global CA tumor marker testing market could potentially be a lucrative field showing continued expansion owing to the spiraling adoption rate of diagnostic services and technologies that are more advanced than the previous ones.

With technological breakthroughs on the cards, projections show that this market will generate abundant opportunities for detecting targeted tumors, monitoring cellular response and for determining genetic predisposition. Furthermore, increased focus on retaining superior quality of life is some of the factors contributing in the growth of this market. However, a rise in the overall healthcare spending, rigid and, in some cases, unfavorable, reimbursement policies, and the high cost of developing new technologies are some of the factors that might act in the opposite direction of the growth of the CA tumor marker testing market.

Request a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11600

CA Tumor Markers Testing Market: Competitive Dynamics

The global CA tumor markers testing market is observed as being a highly fragmented one because of the active participation of many players both established and emerging. The major players involved with the CA tumor markers testing market are Abbott Laboratories, Becton, Dickinson and Company, Applied Genetic Technologies Corporation, bioMérieux SA, Cepheid, Correlogic Systems, Inc., Myriad Genetics, Panacea Pharmaceuticals, Qiagen, Radient Pharmaceuticals, Siemens Healthcare, Targeted Diagnostics & Therapeutics and Thermo Fisher Scientific.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Rising Need for Safe Blood Leads to North America Blood Collection Tubes Market

Transparency Market Research announces the publication of a new market research study titled “Blood Collection Tubes Market - North America Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.” The research study talks about the North America blood collection tubes market, its product segmentation, current trends, key growth drivers, restraints, major geographical segments, and vendor analysis. The study also covers the opportunities available for major players operating in the North America market for blood collection tubes.

As per the research study, in 2014, the North America market for blood collection tubes stood at US$300.8 mn and is predicted to reach US$632.1 mn by the end of 2023. The market is estimated to register a promising 8.60% CAGR between 2015 and 2023. The research study offers insightful inputs by industry experts along with projected figures to help decision-makers in formulating business strategies in an effective manner.

Blood is an important component of the human body and is widely used in hospital for diverse procedures. In addition, millions of blood units are donated across the globe to be used for accident victims, cancer therapies, organ transplantation, and other surgical procedures. Blood plays a crucial role in saving life; however, it can also prove to be fatal as it is considered as a potential vector for several infectious diseases.

The increasing geriatric population and growing prevalence of diseases in developed regions such as North America are some of the key factors expected to fuel the growth of the market throughout the forecast period. The increasing number of diseases affecting the general population is boosting the number of diagnostic blood tests, further driving the overall market. The availability of advanced medical infrastructure in North America is further estimated to augment the growth of the market in the next few years.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8689

The North America market for blood collection tubes has been categorized into rapid serum tubes, heparin tubes, EDTA tubes, serum separating tubes, plasma separation tube, and others. Among these segments, at present, the serum separating tubes segment holds a substantial share in the North America market for blood collection tubes. The North America market for blood collection tubes has been divided on the basis of geography into Canada and the U.S. The research study has included the market share, size, and projected figures of both the regions to give the readers a clear picture of the market.

Furthermore, the research study offers an in-depth vendor analysis of the North America market for blood collection tubes, including detailed company profiles, contact information, business policies, financial status, SWOT analysis, and recent news and developments if any. Some of the prominent players operating in the North America market for blood collection tubes are Terumo Corporation, Becton, Dickinson & Company, Sarstedt AG & Co., Greiner Group AG, QIAGEN N.V., and FL Medical srl.